Xalud Therapeutics, Inc develops therapies initially worked on and developed at the University of Colorado for the treatment of neuro-inflammatory diseases and inflammatory joint disorders including osteoarthritis and rheumatoid arthritis. The company's primary product is XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. The drug treats pain through threating the inflammation that is responsible for the persistent, amplified pain signaling rather than attempting to directly block pain signaling. The firm's therapies have been succesfully tested on dogs and have received numerous acolades.
